The Lombardi Comprehensive Cancer Center's (LCCC) Senior Leadership includes Louis Weiner, MD, Director;Michael Atkins, MD, Deputy Director;six Associate Directors: Anton Wellstein, MD, PhD (Basic &Translational Science Research);Giuseppe Giaccone MD, PhD (Clinical Research);Jeanne Mandelblatt, MD, MPH (Population Science Research);Lucile Adams-Campbell, PhD (Minority Health &Health Disparities Research);Stephen Byers, PhD (Shared Resources);and Michael Vander Hoek, MHSA (Administration);and MedStar Georgetown Cancer Network Representative (Sandra Swain, MD). These individuals constitute the LCCC Executive Committee (EC). As Director, Weiner is responsible for the overall operation and development of the Cancer Center, including its research, educational, and clinical missions. As such he has oversight of the four Research Programs, nine Shared Resources, and all LCCC activities. Atkins, an expert on clinical and translational research, joined as Deputy Director on April 1, 2012. He assists the Director in coordinating Cancer Center activities with specific attention to advancing transdisciplinary research initiatives and integrating clinical research and educational activities within the Cancer Center. EC members guide LCCC's activities with an emphasis on fostering transdisciplinary and translational interactions to achieve the Center's mission. Specifically, the EC oversees Center-wide strategic, operational and educational initiatives;prioritizes overarching goals of the Center related to its mission and comprehensive cancer center status;sets and reviews metrics for each of the respective areas overseen by EC members;prioritizes and oversees developmental funding, resource allocation, and new faculty recruitment;identifies and evaluates new themes and initiatives;reviews opportunities for conducting novel clinical and population research within the MedStar Georgetown Cancer Network to address cancer issues in our local catchment area and nationally;and approves Center membership and membership criteria. Overall, the leadership team brings scientific, clinical, and administrative expertise to all areas of the Center's activities and is ideally structured to help LCCC fulfill its mission.
Lombardi's senior leadership oversees Center-wide strategic and operational initiatives to guide LCCC's activities with an emphasis on fostering transdisciplinary and translational interactions to achieve the Center's mission.
|Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80|
|Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52|
|Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75|
|London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80|
|Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92|
|Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612|
|Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18|
|Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45|
|Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93|
|Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9|
Showing the most recent 10 out of 544 publications